http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박양진(Yang Jin Park),김나리(Nari Kim),김영욱(Young-Wook Kim) 대한외과학회 2011 Annals of Surgical Treatment and Research(ASRT) Vol.80 No.2
Purpose: To know the current trend of the annual number of AAA patients in Korea and treatment modality, we attempted to investigate the numbers of patients diagnosed with AAA and the number of patients who underwent open or endovascular treatment of AAA in Korea during the last 6 years. Methods: To investigate the number of AAA patients, we searched for ruptured AAA and AAA without description of rupture disease from the database of Health Insurance Reimbursement Association (HIRA) by searching the disease code of HIRA I71.3 (ruptured AAA) and I71.4 (AAA without description of rupture) during the period between 2003 and 2009. To investigate the number of patients who underwent treatment for AAA, we searched for code O 2036, O 2034, O 0223, O 0224 (open surgical repair) and M 6612 (endovascular aneurysm repair, EVAR). To discern the number of AAA-related deaths in Korea during the same period, we depended on the database of the Statistics Korea. Results: We found that the number of AAA patients and treatment of AAA were rapidly increasing recently after the inception of the reimbursement for EVAR by the HIRA. But the number of AAA-related deaths did not significantly change during the same period in Korea. Conclusion: After observing that the number of patients with AAA and its treatment rapidly increased while the number of AAA-related death did not increase, we can assume that it is the result of increase of patients detection rather than that of prevalence of AAA and also think that many AAA patients are still under-detected in Korea. To cope with the increasing number of AAA patients and to facilitate detection of hidden AAA patients, we would like to propose a nationwide screening program of AAA for a selected group of the population.
동시에 시행한 관상동맥우회술 및 경동맥 내막절제술과 단계적 수술의 조기 성적 비교
박양진(Yang Jin Park),김동익(Dong-Ik Kim),노영남(Young Nam Roh),김욱성(Wook Sung Kim),이영탁(Young Tak Lee),김경문(Gyeong-Moon Kim),김덕경(Duk-Kyung Kim),김영욱(Young-Wook Kim) 대한외과학회 2011 Annals of Surgical Treatment and Research(ASRT) Vol.80 No.1
Purpose: Between combined and staged operations of carotid endarterectomy (CEA) and coronary artery bypass grafting (CABG) for patients with concurrent coronary and carotid disease, each treatment strategy has its own advantages and disadvantages. We attempted to compare early surgical results between the two operations. Methods: We retrospectively reviewed medical records of 71 patients who underwent either combined CEA & CABG (n=37) or staged CABG & CEA (n=34) in a single institute between January 2001 and March 2010. After comparing patients’ demographics and preoperative neurologic and cardiac status, we compared early (<1 month) postoperative cardiac or neurologic complications and surgical mortality between the 2 groups. Results: There was no significant difference in patients’ demographics and indications for operation the between 2 groups. There were 2 (5.4%) cases of postoperative stroke in combined groups and 1 (2.9%) in staged group. However, there was no myocardial infarction or death. In staged operation group, during the interval time between the two operations, 5 cases (14.7%) of stroke developed, of which, all patients recovered without any sequelae by anticoagulation. Conclusion: After experiencing low postoperative cardiac or neurologic morbidity or mortality after combined CABG and CEA, we conclude that combined CABG and CEA was a safe and feasible treatment option for patients with neurologic symptoms and in stable cardiac status. In the staged operation group of patients, we observed development of neurologic events during the interval period between CABG and CEA. To attain optimal treatment strategy in asymptomatic patients, further prospective study would be required.
이진욱(Jin Wook Yi),정인목(In Mok Jung),이태승(Taeseung Lee),민승기(Seung-Kee Min),민상일(Sang Il Min),박양진(Yang Jin Park),하종원(Jongwon Ha),정중기(Jung Kee Chung),김상준(Sang Joon Kim) 대한외과학회 2010 Annals of Surgical Treatment and Research(ASRT) Vol.79 No.6
Purpose: Acute ischemia of the arm is uncommon compared with events in the leg and much less attention has been paid to the management of acute arterial thromboembolism of the upper extremities. The aim of this study was to evaluate the clinical aspects and treatment outcomes of acute upper extremity thromboembolism. Methods: From January 2007 to March 2010, seven patients underwent the management of upper extremity thromboembolism in three Seoul National University (SNU)-affiliated hospitals. We retrospectively reviewed the medical records. Results: The mean age was 64.6 years (range 48∼93 years) and 4 patients (57.1%) were female. Distribution of the thromboembolism were 4 in brachial, 1 in axillary plus brachial, 1 in ulnar and radial, and 1 in axillary artery, respectively. Time from symptom onset to presentation was 3.5 days (range 1∼10 days). Primary treatment modality were Fogarty catheter embolectomy in 3 cases, bypass surgery in 1 case, and urokinase thrombolysis in 2 cases. A patient without symptoms was treated conservatively. Patients receiving primary thrombolytic therapy underwent surgical approach due to recurred thromboembolism during admission. In our 11.2 months of mean follow-up, there was recurrence but 1 patient died from cerebral infarction after 1.5 year of discharge. Conclusion: In this study, functional outcome of acute upper extremity ischemia following appropriate treatments was excellent. Key features of treatment are shortening the time interval of diagnosis to primary treatment, proper anticoagulation, and treatment of underlying conditions. Larger-volume, long-term results and meta-analysis of upper extremity thromboembolism are required to establish standardized treatment in Korea.
신이식 환자에서 마이코페놀레이트 병합을 통한 싸이클로스포린 감량요법의 전향적 연구결과
강진모(Jinmo Kang),박양진(Yang Jin Park),하종원(Jongwon Ha),이태승(Taeseung Lee),정중기(Jungkee Chung),김연수(Yon Su Kim),안규리(Curie Ahn),김상준(Sang Joon Kim) 대한외과학회 2008 Annals of Surgical Treatment and Research(ASRT) Vol.74 No.4
Purpose: Although cyclosporine (CsA) improves short-term renal graft outcomes, many paradigms reduce or withdraw this drug because of its nephrotoxicity. However, inadequate immunosuppression with azathioprine led to little success. We conducted a prospective study to define the prolonged effect of CsA reduction in stable renal transplant recipients with mycophenolate mofetil (MMF). Methods: Thirty-nine primary renal transplant recipients were divided into two cohorts, the AZA (N=13) and the MMF cohort (N=26). Both cohorts were allowed to reduce the CsA dose up to 50% of baseline within 3 to 4 months of conversion to AZA or MMF. Graft function, clinical parameters, and adverse events were monitored for up to 3 years. Results: Ccr gradually deteriorated in the AZA cohort, but was stable in the MMF cohort. There was no episode of acute rejection or graft loss observed in either cohort. Conclusion: The CsA dose can be reduced in combination with MMF treatment in stable renal transplant recipients after 2 years of transplantation, resulting in beneficial effects on Ccr, lipid profiles, and blood pressure.